Posted by Michael Wonder on 18 Jan 2023
Maribavir for the treatment of patients with a refractory cytomegalovirus infection after transplant
18 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of maribavir in the NHS in England.
Maribavir is recommended as an option for the treatment of adults with a cytomegalovirus infection that is refractory to treatment including cidofovir, foscarnet, ganciclovir or valganciclovir following haematopoietic stem cell or solid organ transplantation.
